No mention of upcoming trial data to be announced. Though it does say full recruitment of KEYNOTE in Feb 2018, which is coincidental.
It would be nice to be able to make a fair assessment on the worth of the company based on the information Merck will have in relation to the status of the trial data coming from KEYNOTE.
With 50 to 60 million in cash and 93 million in accumulated tax losses (that I assume can be used), that is a lot a value even before we calculate the value potential of the drug they have in trial.
Merck are getting a steal.
VLA Price at posting:
$1.66 Sentiment: Buy Disclosure: Held
